Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.51 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.51 |
| ▸ | RAB9A | P51151 | 6/20 | 0.49 |
| ▸ | NPC1 | O15118 | 5/20 | 0.49 |
| ▸ | NOS2 | P35228 | 2/20 | 0.42 |
| ▸ | MAOB | P27338 | 6/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.40 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.40 |
| ▸ | MEN1 | O00255 | 2/20 | 0.40 |
| ▸ | LMNA | P02545 | 1/20 | 0.40 |
| ▸ | TP53 | P04637 | 1/20 | 0.40 |
| ▸ | PKM | P14618 | 1/20 | 0.40 |
| ▸ | MAPT | P10636 | 1/20 | 0.40 |
| ▸ | HPGD | P15428 | 1/20 | 0.39 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.39 |
| ▸ | MAOA | P21397 | 2/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6863046 | 0.84 | MAPK1 (0.51) | ALDH1A1MAPK1RAB9ANPC1NOS2 | |
| SCHEMBL11990102 | 0.84 | MAPK1 (0.48) | ALDH1A1MAPK1RAB9ANPC1MAOB | |
| SCHEMBL13803829 | 0.84 | ALDH1A1 (0.51) | ALDH1A1MAPK1RAB9ANPC1NOS2 | |
| SCHEMBL11989287 | 0.84 | ALDH1A1 (0.48) | ALDH1A1MAPK1RAB9ANPC1NOS2 | |
| SCHEMBL778933 | 0.82 | NPC1 (0.50) | ALDH1A1MAPK1RAB9ANPC1NOS2 | |
| SCHEMBL13604916 | 0.79 | ALDH1A1 (0.43) | ALDH1A1MAPK1RAB9ANPC1MAOB | |
| SCHEMBL257873 | 0.78 | ALDH1A1 (0.69) | ALDH1A1MAPK1RAB9ANPC1MAOB | |
| SCHEMBL6165864 | 0.77 | ALDH1A1 (0.78) | ALDH1A1MAPK1RAB9ANPC1MAOB | |
| SCHEMBL26186440 | 0.73 | AR (0.39) | ALDH1A1KMT2ASMN1; SMN2MEN1LMNA | |
| SCHEMBL14919976 | 0.73 | MAPK1 (0.49) | ALDH1A1MAPK1RAB9ANPC1NOS2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20140206865-A1 | Human Adam-10 Inhibitors | SYMPHONY EVOLUTION, INC. (US) | 2014-07-24 | — | — | US | disclosed |
| US-20140206865-A1 | Human Adam-10 Inhibitors | SYMPHONY EVOLUTION, INC. (US) | 2014-07-24 | — | — | US | disclosed |
| US-20130144056-A1 | Human Adam-10 Inhibitors | SYMPHONY EVOLUTION, INC. (US) | 2013-06-06 | — | — | US | disclosed |
| US-20130144056-A1 | Human Adam-10 Inhibitors | SYMPHONY EVOLUTION, INC. (US) | 2013-06-06 | — | — | US | disclosed |
| US-20120270884-A1 | Methods of Treating Aneurysmal Dilatation, Blood Vessel Wall Weakness and Specifically Abdominal Aortic and Thoracic Aneurysm Using Matrix Metalloprotease-2 Inhibitors | SYMPHONY EVOLUTION, INC. (US) | 2012-10-25 | — | — | US | disclosed |
| US-8247451-B2 | ADAM10 and its uses related to infection | VANDERBILT UNIVERSITY (US) | 2012-08-21 | — | — | US | disclosed |
| US-8247451-B2 | ADAM10 and its uses related to infection | VANDERBILT UNIVERSITY (US) | 2012-08-21 | — | — | US | disclosed |
| US-20120071653-A1 | Human Adam-10 Inhibitors | SYMPHONY EVOLUTION, INC. (US) | 2012-03-22 | — | — | US | disclosed |
| US-7989661-B2 | Human ADAM-10 inhibitors | SYMPHONY EVOLUTION, INC. (US) | 2011-08-02 | — | — | US | disclosed |
| US-20110082114-A1 | Methods of Treating Aneurysmal Dilatation, Blood Vessel Wall Weakness and Specifically Abdominal Aortic and Thoracic Aneurysm Using Matrix Metalloprotease-2 Inhibitors | SYMPHONY EVOLUTION, INC. (US) | 2011-04-07 | — | — | US | disclosed |
| US-20100105953-A1 | Human Adam-10 Inhibitors | SYMPHONY EVOLUTION, INC. (US) | 2010-04-29 | — | — | US | disclosed |
| US-7629341-B2 | e.g. N1-hydroxy-N2-[(4-phenoxyphenyl)sulfonyl]-D-argininamide; metallopeptidase inhibitor; antiinflammation, anticarcinogenic, antidiabetic agent; angiogenesis inhibitor; atherosclerosis, stroke, ulcer, infertility, scleroderma, endometriosis, mesothelioma | SYMPHONY EVOLUTION, INC. (US) | 2009-12-08 | — | — | US | disclosed |
| US-20090220514-A1 | ADAM10 and its Uses Related to Infection | VANDERBILT UNIVERSITY | 2009-09-03 | — | — | US | disclosed |
| US-20090220514-A1 | ADAM10 and its Uses Related to Infection | VANDERBILT UNIVERSITY | 2009-09-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120270884-A1 | Methods of Treating Aneurysmal Dilatation, Blood Vessel Wall Weakness and Specifically Abdominal Aortic and Thoracic Aneurysm Using Matrix Metalloprotease-2 Inhibitors | ADAM10, ADAM17, ADAM12 | ALDH1A1 2454/4885MAPK1 3489/4885RAB9A 2919/4885 |
| US-20120071653-A1 | Human Adam-10 Inhibitors | ADAM10, MMP20, ADAM9 | ALDH1A1 541/4885MAPK1 1305/4885RAB9A 523/4885 |
| US-20100105953-A1 | Human Adam-10 Inhibitors | ADAM10, MMP20, ADAM9 | ALDH1A1 541/4885MAPK1 1305/4885RAB9A 523/4885 |
| US-20110082114-A1 | Methods of Treating Aneurysmal Dilatation, Blood Vessel Wall Weakness and Specifically Abdominal Aortic and Thoracic Aneurysm Using Matrix Metalloprotease-2 Inhibitors | ADAM10, ADAM17, ADAM12 | ALDH1A1 2168/4885MAPK1 3097/4885RAB9A 2899/4885 |
| US-20090220514-A1 | ADAM10 and its Uses Related to Infection | ADAM10, ADAM12, ADAM17 | ALDH1A1 4310/4885MAPK1 2110/4885RAB9A 661/4885 |
| US-20140206865-A1 | Human Adam-10 Inhibitors | ADAM10, MMP20, ADAM9 | ALDH1A1 541/4885MAPK1 1305/4885RAB9A 523/4885 |
| US-20130144056-A1 | Human Adam-10 Inhibitors | ADAM10, MMP20, ADAM9 | ALDH1A1 541/4885MAPK1 1305/4885RAB9A 523/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.